This article was originally published on Microdose Psychedelic Insights, and appears here with permission.
Canada’s health minister, Patty Hajdu, is appealing to the government of Alberta to keep their injectable opioid agonist treatment program open. The controversial, yet effective program provides patients diagnosed with severe opioid use disorder with injections of pharmaceutical-grade heroin (diacetylmorphine) or hydromorphone (also known as Dilaudid). Premier Jason Kenney intends to stop funding the program in the spring, despite it being a hallmark effort in the government’s strategy to battle the raging opioid epidemic.
In a recent report by CBC News, a spokesperson for Hajdu is quoted as saying, “We are disappointed by this decision from the Alberta government, and we urge them to reconsider.” With 170 drug overdose deaths recorded for B.C. in May alone, the pressure to address this epidemic is greater than ever before.
From Psychedelic Medicine to Harm Reduction: Hajdu’s Push for Progressive Policies
Hadju’s push to keep Alberta’s injectable opioid agonist treatment program open is her latest in a string of diligent efforts to establish more progressive drug policy in Canada. Following concerted advocacy efforts by TheraPsil earlier this year, Hajdu historically approved four Canadians with terminal cancer for psilocybin therapy. This massive milestone was not only a victory for the movement to medicalize psychedelic drugs, but for the greater push towards better mental healthcare across the world.
The Intersection of Psychedelics, Addiction & Global Drug Policy
Based on the groundbreaking clinical research, psychedelic medicine is indeed presenting itself to be a radical solution–but to what? The simple fact of the matter is …